The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country.
Patients who have been treated with one round of chemotherapy for metastatic pancreatic cancer and have stable disease as determined by screening may be eligible to enroll at Georgetown Lombardi; Thomas Jefferson University; Cedars-Sinai in Los Angeles; Virginia Mason in Seattle; and Mount Sinai in New York.
The phase II study will enroll about 60 patients. Half will be randomly assigned to receive standard-of-care chemotherapy regimens, and the other half will have their tumors analyzed using state-of-the-art laboratory tests designed to match treatment to the genes and proteins making their cancers grow and spread. (The patient’s insurance company will be billed for molecular tests, but a copay or surcharge may be applied.)
I am certain we will learn a lot about what drives pancreatic cancer, what we can use in our medical toolkit, and what we need to develop as novel treatments.— Michael J. Pishvaian, MD, PhD
Tweet this quote
“In the molecularly tailored group, we will be harnessing any and all available resources to provide patients with the right drugs to treat their tumors,” says Georgetown Lombardi oncologist Michael J. Pishvaian, MD, PhD, principal investigator of the clinical trial, who sees patients at MedStar Georgetown University Hospital.
“We may find that some patients do better with standard-of-care therapy because their tumors use pathways for which we do not have a targeted therapy, and that other patients respond well to targeted treatments for which we have an agent,” Dr. Pishvaian explained. “I am certain we will learn a lot about what drives pancreatic cancer, what we can use in our medical toolkit, and what we need to develop as novel treatments.”
Trial Support
The $1 million study is being funded by the American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network (PanCAN). The other co-leading institution is Thomas Jefferson University in Philadelphia, which will molecularly model individual tumors.
The award to Georgetown Lombardi and Thomas Jefferson University recognizes “the urgent need for research into this deadly disease,” said Margaret Foti, PhD, MD (hc), AACR Chief Executive Officer, when the clinical trial was announced this past year.
“Pancreatic cancer is one of the few cancer types for which death rates are steadily increasing; it is projected to become the second leading cause of cancer-related death in the United States by 2030,” Dr. Foti said.
The study is also being funded or supported in part by Caris Life Sciences, Inc; Guardant Health, Inc; and Theranostics Health, Inc. Dr. Pishvaian has been a paid advisor and paid speaker for Caris Life Sciences.
For more information about this or other cancer clinical trials, please call Georgetown Lombardi at 202-444-2223, and press 3. ■
